Гинофлор Э


13 Май 2015
Phase I pharmacokinetic (PK) study assessed circulating estrogens in breast cancer (BC) patients on anon-steroidal aromatase inhibitor (NSAI) with vaginal atrophy using vaginal ultra-low-dose 0.03 mg estriol (E3) and Lactobacillus combination vaginal tablets (GynoflorÒ)

Скачать полный текст статьи: «Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study»